Intravenous immunoglobulin-induced, non-eczematous, vesiculobullous eruptions in Stevens-Johnson syndrome.

Abstract

Intravenous immunoglobulin (IVIG) has emerged as a promising treatment that interrupts the progression of Stevens-Johnson syndrome (SJS). Our patient experienced an uncommon adverse effect, non-eczematous, vesiculobullous eruptions, after treatment with IVIG. These new lesions developed rapidly on the palms while most previous SJS bullous lesions subsided. A skin biopsy of these new lesions showed an intracorneal vesicle, without epidermal necrosis, with inflammatory cell infiltration. IVIG-induced, vesiculobullous eruptions are discussed, along with their possible pathogenesis. With the increasing use of IVIG for treatment of bullous dermatoses, recognition of this rare adverse effect is important for prompt differential diagnosis.

• Authors: Wan-Lung Lin, Wen-Chi Lin, Ya-Ching Chang, Li-Cheng Yang, Shuen-Iu Hung, Hong-Shang Hong, Wen-Hung Chung
• Journal: American journal of clinical dermatology (Am J Clin Dermatol) Vol. 10 Issue 5 Pg. 339-42 ( 2009) ISSN: 1175-0561 [Print] New Zealand
• PMID: 19658448 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Immunoglobulins, Intravenous
• Immunologic Factors

Topics

• Biopsy
• Diagnosis, Differential
• Female
• Hand Dermatoses (chemically induced, diagnosis)
• Humans
• Immunoglobulins, Intravenous (adverse effects, therapeutic use)
• Immunologic Factors (adverse effects, therapeutic use)
• Middle Aged
• Skin Diseases, Vesiculobullous (chemically induced, diagnosis)
• Stevens-Johnson Syndrome (drug therapy)